Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Reducing stroke damage may be next for optical coherence tomography technology widely used in vision healthcare

  • Uncovering the mechanism of our oldest anesthetic

  • Health information causing new moms anxiety

  • Statins linked to lower aggression in men, but higher in women

  • Lifelong learning is made possible by recycling of histones, study says

  • REM sleep critical for young brain development; medication interferes

  • How the stress hormone cortisol reinforces traumatic memories

  • Can autism be measured in a sniff?

  • Electrical nerve stimulation can reverse spinal cord injury nerve damage in patients

  • Brain activity predicts promiscuity and problem drinking

  •